We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our vision is to contribute to a world in which no one dies or suffers from a vaccine-preventable disease.
Valneva at a glance
3
Commercial vaccines
€~169.6m
Total revenues in 2024
3
Unique vaccine development programs
Integrated
differentiated clinical and pre-clinical assets
robust commercial portfolio
Focused
on prevention of infectious diseases with significant unmet medical need
>700
employees in six countries